Aviptadil
Cardiovascular & vascular
Early humanHuman research includes an exploratory 20 participant pulmonary hypertension study and COVID-19 respiratory failure trials.
Limited, exploratory, early phase or small human studies have been identified.
What is Aviptadil?
Aviptadil is a synthetic formulation of vasoactive intestinal peptide (VIP) used as a pulmonary and vascular research reagent; the catalogue label denotes the research grade peptide material employed in early human and preclinical studies.
Which research context has Aviptadil been associated with?
Aviptadil is associated with cardiovascular and pulmonary research as a synthetic vasoactive intestinal peptide (VIP) analogue, investigated in human studies for exploratory pulmonary hemodynamic effects, small pulmonary hypertension trials, and respiratory failure research including COVID 19 trials.
What documentation is available for Aviptadil?
Aviptadil: Batch documents are not yet linked on this site. Required evidence for this synthetic VIP analogue includes batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and stated purity; peptide content, counterion and residual solvent/water specification; and potency or biological assay used for release. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Aviptadil?
Aviptadil: Storage depends on the documented supplied presentation; for this synthetic VIP analogue confirm whether delivered dry/lyophilised or in solution, counterion and concentration, solvent or buffer composition, pH stability, container closure interactions and freeze/thaw tolerance as these impact peptide integrity and aggregation. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.